Skip to main content
All lobbying filings

NOVOCURE INC.

Lobbying for NOVOCURE INC.

 Filing 2nd Quarter - Report
2nd Quarter (Apr 1 - June 30) 2026 · Pennsylvania · House · Senate · $160,000.00 expenses · posted Jul 19, 2026

Official filing document

 Bills named in this filing 2
  • HR 5343
    Ensuring Patient Access to Critical Breakthrough Products Act
  • S 1717
    Ensuring Patient Access to Critical Breakthrough Products Act of 2025
 Lobbying activity 2
Tariff (miscellaneous tariff bills)

Tariff issues, specifically related to medical device 232.

Medicare/Medicaid

General Medicare Issues. H.R.5343/S.1717 - Ensuring Patient Access to Critical Breakthrough Products Act of 2025.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem